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Summary
Objective: The present study examined whether local administration of the neuropeptide vasoactive intestinal polypeptide (VIP) could mod-
ulate joint nociception in normal rat knee joints and if the VIP antagonist VIP6e28 could ameliorate joint mechanosensitivity in an animal model
of osteoarthritis (OA).
Methods: OA was induced in male Wistar rats by intra-articular injection of 3 mg sodium monoiodo-acetate with a recovery period of 14 days.
Electrophysiological recordings were made from knee joint primary afferents in response to normal rotation and noxious hyper-rotation of the
joint both before and following close intra-arterial injection of different doses of VIP and VIP6e28.
Results: Local application of VIP to normal knees caused afferent ﬁring rate to be signiﬁcantly enhanced during normal rotation (up to 180%
P< 0.01; n¼ 17) and during hyper-rotation (up to 37% P< 0.01; n¼ 17) of the knee. VIP-induced sensitization was blocked by pre-
administration of the VIP receptor antagonist VIP6e28. In the OA group, application of VIP6e28 caused afferent ﬁring rate to be signiﬁcantly
reduced during normal rotation (up to 45% P< 0.05; n¼ 17) and during hyper-rotation (up to 34% P< 0.01; n¼ 15) of the knee joint.
Conclusion: These ﬁndings indicate that VIP is involved in peripheral sensitization of knee joint afferents especially in response to normal joint
movements. OA-induced sensitization of knee joint afferents was inhibited by local administration of VIP6e28, indicating that VIP is released
into OA knee joints, potentially contributing to joint pain. As such, VIP6e28 may prove to be a beneﬁcial agent for the treatment of arthritis pain.
ª 2006 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Osteoarthritis (OA) is a degenerative disease characterized
by extensive remodelling of subchondral bone and perma-
nent destruction of articular cartilage leading to structural
and functional degradation of affected synovial joints. Pa-
tients with OA have pain that typically worsens with weight
bearing and activity. Currently, no disease modifying drugs
are available, therefore treatment of OA is still restricted to
analgesics which often have limited efﬁcacy and hazardous
side-effects. Therefore, identiﬁcation of the mediators re-
sponsible for the initiation and maintenance of joint pain in
OA is needed to develop speciﬁc agents to counteract the
debilitating symptoms of this disease.
One of the main mechanisms responsible for the genera-
tion of joint pain is the activation of nociceptors located on
the terminal branches of joint type III (Ad ﬁbre) and type
IV (C ﬁbres) primary afferents. One important family of
agents known to be involved in the peripheral sensitization
of joint afferents are inﬂammatory neuropeptides, such as
substance P, nociceptin and calcitonin gene-related pep-
tide. These potent neurotransmitters are synthesized in dor-
sal root ganglia and stored in the terminal branches of type
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Received 14 March 2006; revision accepted 18 April 2006.11III and IV ﬁbres where their release into the joint leads to
peripheral sensitization1e5. Inhibition of joint nociceptor
activity would reduce noxious sensory input to the central
nervous system thereby moderating the sensation of arthri-
tis pain.
Vasoactive intestinal polypeptide (VIP) is a 28 amino acid
neuropeptide which is contained in postganglionic sympa-
thetic as well as capsaicin-sensitive sensory nerve ﬁbres in-
nervating the joint capsule6e8. VIP is known to bind to two
G-protein-coupled receptors (VPAC1 and VPAC2)9. VPAC
receptors are expressed in the rat dorsal horn of the spinal
cord where they are involved in the central modulation of
sensory information10. The function of VIP in joints is still
unclear, but local administration of the peptide has been
shown to cause synovial hyperaemia in the rat knee sug-
gesting that VIP may be involved in the control of joint in-
ﬂammation11. Whether VIP contributes to arthritis pain, as
has been demonstrated with other inﬂammatory neuropep-
tides, is unknown.
Animal models of inﬂammatory joint disease have been
used in several studies to investigate mechanosensitivity
changes and joint pain2,5,12. Since inﬂammation is generally
considered to be a secondary component of OA, then it
would be interesting to determine the neurophysiological
characteristics of OA pain using a suitable animal model.
Although animal models of OA are prevalent, they have
mainly been used to study the pathophysiology and pro-
gression of joint damage with little characterization of the
associated pain13e15. One useful model of OA involves55
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sodium iodoacetate (MIA) which disrupts chondrocyte
metabolism, produces cartilage degeneration and subchon-
dral bone lesions consistent with the pathological changes
seen in the human condition15,16.
The aim of the present study was to establish whether
VIP is involved in the mechanosensitivity of knee joint affer-
ents and whether the VPAC receptor antagonist VIP6e28
could block these responses. We also investigated the elec-
trophysiological characteristics of mechanosensory nerves
in the MIA model of OA, and determined whether VIP6e28
could modulate joint nociception in an OA knee joint.
Methods
ANIMALS
Experiments were performed on 33 male Wistar rats
(250e450 g) which were housed in cages at room temper-
ature (22(C) under a 12:12 h light/dark cycle with free ac-
cess to water and rodent food. The animal handling and
surgical procedures outlined in this study all adhered to
the Canadian Council guidelines for the care and use of
experimental animals.
SURGICAL PROCEDURES
Rats were deeply anaesthetized with urethane (25% stock
solution; 2 g/kg, intraperitoneal (i.p.)) before the commence-
ment of any surgical procedures. Depth of anaesthesia was
conﬁrmed by the absence of the hindpaw withdrawal reﬂex.
Core body temperature was measured by a rectally inserted
thermometer and maintained at 37(C by a thermostatically
controlled heating blanket. The trachea was cannulated
and connected to a Harvard rodent respiratory pump for arti-
ﬁcial ventilation with 100% O2 (stroke volume of 2.5 ml,
breath frequency set at 60 breaths/min). The left carotid ar-
tery was then cannulated with a ﬁne bore catheter (Portex
Fine Bore Tubing, 0.5 mm Internal Diameter (ID), 1.00 mm
Outer Diameter (OD); SIMS Portex Ltd., Kent, England) con-
taining heparinised saline (100 units/ml). The cannula was
connected toapressure transducer to allowcontinuousblood
pressure measurement as recorded by a pressure monitor
(BP-1, World Precision Instruments, Sarasota, FL, USA).
The left jugular vein was also cannulated (Portex Fine Bore
Tubing, 0.40 mm ID, 0.80 mm OD; SIMS Portex Ltd., Kent,
England) and a single administration of the muscle relaxant
gallamine triethiodide (50 mg/kg) was injected through the
catheter to eliminate neural interference arising from the hin-
dlimbmusculature. Finally, a catheterwas introduced into the
right saphenous artery below the knee joint and advanced to
a point just distal to the bifurcation with themedial articular ar-
tery to permit local close intra-arterial injection of drugs to the
knee joint. The central portion of the right femur was isolated
andaspecialised clampwas ﬁxed to themid-shaft of thebone
and attached to a stereotaxic frame to immobilise the proxi-
mal aspect of the rat hindlimb. The right hindpaw was then
placed in a shoe-like holder which was connected to a force
transducer and torque meter (MVD2510; Hottinger-Baldwin
Messtechnik, Darmstadt, Germany) to standardize the
amount of rotational force being applied to the knee joint.
Finally, a longitudinal skin incision was made along the
medial aspect of the hindlimb and the resulting skin ﬂaps
were secured to a metal ‘‘O’’ ring to create a pouch which
was ﬁlled with warm parafﬁn oil. This oil pool served to pre-
vent tissue desiccation throughout the experiment.EXTRACELLULAR ELECTROPHYSIOLOGICAL RECORDING
The technique used for recording units from rat knee
joint afferents has been described previously5,17. Brieﬂy,
the saphenous nerve was transected distally to the knee
joint to eliminate sensory input from the foot and ankle re-
gion. The saphenous nerve was also isolated in the ingui-
nal region and cut centrally to prevent the generation of
spinally mediated reﬂexes. The saphenous nerve stump
projecting centrally from the knee was placed on a small,
black Perspex stage to facilitate the isolation of ﬁne neu-
roﬁlaments which were dissected free from the nerve us-
ing ﬁne watchmaker forceps. Nerve ﬁbres were then
placed over a platinum electrode to permit extracellular
recordings. Afferent nerve ﬁbres originating from the
knee joint were identiﬁed by the elicitation of a response
to gentle probing of the knee joint with a glass rod with
a 1 mm tip. The conduction velocity of the nerve ﬁbres
was ascertained by electrically stimulating their receptive
ﬁeld with a pair of bipolar, silver wire electrodes (1 Hz,
100 ms pulse width, 3e10 V); the distance between stim-
ulating and recording electrodes was divided by the la-
tency between stimulus artefact and evoked afferent
impulse to give the conduction velocity. The electrical
threshold of each ﬁbre was determined by placing the bi-
polar silver electrode in the receptive ﬁeld of the ﬁbre and
gradually increasing the voltage of stimulation in 0.5 V
steps until the pulse elicited spike discharges of the affer-
ent. The mechanical threshold of individual units was also
determined by slowly rotating the knee until nerve activity
could be detected and noting that the force on the torque
meter required to elicit such a response. The mechano-
sensitivity of articular afferents was tested by recording
nerve activity in response to outward non-noxious rotation
and noxious hyper-rotation of the knee joint. Non-noxious
rotation is described here as occurring within the normal
working range of the joint while noxious hyper-rotation of
the joint is deﬁned here as being outside the normal work-
ing range of the knee without imparting overt tissue
trauma. This level of joint rotation causes maximal activa-
tion of joint primary afferents which would result in a pain-
ful sensation in an alert animal. The amount of force
required to produce this noxious mechanical stimulus
was between 20 and 40 mNm. Three movement cycles
consisting of a normal and hyper-rotation of the knee
were performed at the beginning of the experiment and
the mean afferent ﬁring rate associated with these move-
ments constituted the control baseline level which was set
at 100%. Each movement lasted 10 s and the same level
of rotation was repeated every 2 min until 15 min after
drug application. After ﬁbre activity returned to control
levels, the next dose of drug was applied to the knee.
In the normal group of animals, recordings were made be-
fore (control) and after close intra-arterial injection of VIP
(1012e109 mol; 0.1 ml bolus). In separate experiments,
the VIP receptor antagonist VIP6e28 (10
9 mol; 0.1 ml
bolus) was administered prior to each dose of VIP to con-
ﬁrm VPAC receptor involvement in joint mechanosensitiv-
ity. In a separate group of normal rats a doseeresponse
relationship to VIP6e28 (10
11e109 mol) was examined.
Neuronal activity was digitised by a data acquisition sys-
tem (CED1401, Cambridge Electronic Design, Cambridge,
UK) and stored on a microcomputer for off-line analysis.
The number of action potentials/movement was deter-
mined using Spike 2 software (Cambridge Electronic De-
sign, Cambridge, UK) and the % change in afferent
activity was calculated.
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Eleven rats were deeply anaesthetised with 2% isoﬂur-
ane in 100% O2 (1 l/min) until the ﬂexor withdrawal
reﬂex was abolished. The skin overlying the right knee
joint was shaved and swabbed with 100% ethanol and
the diameter was measured across the joint line in a
medio-lateral plane using a digital micrometer (Mitutoyo
Instruments, Tokyo Japan). A 27-guage needle was intro-
duced into the joint cavity through the patellar ligament
and 50 ml of 3 mg sodium monoiodoacetate in 0.9% saline
was injected into the joint to induce OA-like lesions. Ani-
mals were allowed to recover for 14 days which has consis-
tently been shown to be a sufﬁcient duration for the
development of OA in this species14,16,18. This was con-
ﬁrmed in our experiments in which joint diameter was
signiﬁcantly increased at this time point. Recordings from
OA knee joints were carried out as described above and
the effect of close intra-arterial injection of VIP6e28
(1011e109 mol; 0.1 ml bolus) on joint mechanosensitivity
was assessed. Sham injected animals were not used in
this study since previous behavioural experiments have
conﬁrmed that intra-articular administration of saline does
not cause a painful response19.
DRUGS AND REAGENTS
Sodium monoiodoacetate, VIP, VIP6e28, gallamine trie-
thiodide and urethane were obtained from SigmaeAldrich
(Ontario, Canada). VIP and VIP6e28 were dissolved in
0.9% saline and aliquots of the drug were kept frozen
(20(C) in Eppendorf vials until required. Gallamine trie-
thiodide was made fresh on the day of experimentation
and dissolved in 0.9% saline.
STATISTICS
All data were expressed as means S.E.M. for ‘‘n’’ ﬁbres.
The effect of drugs between animal groups was analysed
by two-way ANOVA with a Bonferroni post-test and un-
paired Student’s t test. Dose dependency and time course
of drugs were tested by one-way ANOVA with individual
points being compared using a one-sample t test. All differ-
ences were considered statistically signiﬁcant at a P value
less than 0.05. All data passed a normality test; therefore
a Gaussian distribution can be assumed and parametric
statistics were applied.
Results
ELECTROPHYSIOLOGICAL RECORDINGS
Between 1 and 3 afferent ﬁbres were examined per ani-
mal such that a total of 47 units were recorded in this study.
The electrophysiological characteristics of these units are
summarized in Table I. All units tested could be activated
by injection of potassium chloride (KCL) (0.4 mM, 0.1 ml)
at the end of the experiment conﬁrming that administered
drug solutions reached mechanosensory nerve endings
[Fig. 7(C)]. The conduction velocities for the recorded ﬁbres
ranged from 0.92 to 11.16 m/s which under the joint afferent
classiﬁcation system20 conﬁrmed them as either type III or
type IV knee joint afferents. Fibres responded to outward ro-
tation of the knee and had a mechanical threshold which
was within the normal working range of the knee joint, i.e.,
typically only low threshold units were recorded. One ﬁbrewith a high mechanical threshold (i.e., responsive only to
noxious movements) was also included in the study.
EFFECT OF VIP AND VIP6e28 ON MECHANOSENSITIVITY
OF NORMAL KNEE JOINTS
Application of VIP caused afferent ﬁring rate to be signif-
icantly enhanced during normal rotation and noxious hyper-
rotation of the knee joint. The sensitizing effect of VIP was
maximal 3 min after drug application for both types of me-
chanical stimuli (one-sample t test P< 0.01; Fig. 1). The
Table I
Proportion and electrophysiological characteristics of thinly myelin-
ated type III and unmyelinated type IV units recorded from normal
and OA knee joints (MT¼mechanical threshold; ET¼ electrical
threshold; CV¼ conduction velocity)
MT (mNm) ET (V) CV (m/s) % of
ﬁbres
Normal joints Type III 2e11 3.5e8 2.5e4.5 42
Type IV 2e12 3e9 0.9e2.3 58
OA joints Type III 2e6 3e6 2.9e11.2 28
Type IV 3e9 3e8 1.3e2.4 72
Fig. 1. Effect of close intra-arterial injection of VIP (109 mol) on
knee joint afferent activity in response to non-noxious (A) and
noxious (B) rotation of the knee joint compared to control (repre-
sented by dotted line set at 100%). Sensitizing effect of VIP was
maximal after 3 min. Data are shown as mean S.E.M.. *P< 0.05;
**P< 0.01; ***P< 0.001; one-sample t test; n¼ 17 ﬁbres.
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across the dose range 1012e109 mol, for non-noxious
and noxious movements (one-way ANOVA; P< 0.05;
Fig. 2). VIP enhanced ﬁring rate during normal rotation by
up to 180% and during noxious hyper-rotation by up to
37%. High dose VIP caused spontaneous activity in a
subgroup of joint ﬁbres which lasted for several minutes.
VIP-induced sensitization of joint afferents was blocked by
pre-administration of the VIP receptor antagonist VIP6e28
(109 mol; two-way ANOVA P< 0.01; Fig. 2). Close intra-
arterial administration of VIP6e28 (10
11e109 mol) alone
into normal knee joints had no signiﬁcant effect on nerve ﬁ-
bre mechanosensitivity (Fig. 6). Specimen recordings
showing the sensitizing effect of VIP and the attenuation
of this response by VIP6e28 are shown in Fig. 3.
EFFECT OF VIP6e28 ON MECHANOSENSITIVITY OF OA
KNEE JOINTS
The average ﬁring rate of afferents in the OA knee joint
was signiﬁcantly increased during normal and noxious hy-
per-rotation (unpaired Student’s t test P< 0.001; Fig. 4)
compared to the ﬁring rate in the normal control group. In
Fig. 2. Doseeresponse relationship showing the effect of VIP on
normal knee joint afferent mechanosensitivity in response to non-
noxious (A) and noxious (B) rotation of the knee joint. The sensitiz-
ing effect of peripheral VIP administration was signiﬁcant across the
entire dose range (one-way ANOVA P< 0.05). Pre-administration
of the VIP antagonist VIP6e28 attenuated the effect of VIP (two-way
ANOVA P< 0.001; n¼ 17 ﬁbres; Bonferroni post-test *P< 0.05;
**P< 0.01; ***P< 0.001). Data are means S.E.M.the OA knee joint, application of VIP6e28 caused afferent ﬁr-
ing rate to be signiﬁcantly reduced during normal rotation
and during noxious hyper-rotation of the knee joint. This
desensitizing effect was maximal 3 min after VIP6e28 ad-
ministration (Fig. 5) and was found to be dose dependent
(one-way ANOVA P< 0.05; Fig. 6). The 109 mol dose of
VIP6e28 reduced ﬁring rate during normal rotation by up to
45% and during noxious hyper-rotation by up to 34%. A
subgroup of afferents in the OA knee joint showed sponta-
neous activity which could be blocked or reduced by
VIP6e28 for several minutes. A specimen recording showing
the inhibitory effect of VIP6e28 on afferent nerve activity in
an OA joint is shown in Fig. 7.
Discussion
VIP AND JOINT NOCICEPTION
Sensory neuropeptides such as substance P and
nociceptin are known to sensitize joint afferents leading to
Fig. 3. Specimen recording of a single unit to passive movement
(non-noxious and noxious) of the knee joint (A). Close intra-arterial
application of VIP caused a profound sensitization of the afferent ﬁ-
bre (B). Pre-administration of the VIP antagonist VIP6e28 signiﬁ-
cantly inhibited the sensitizing effect of VIP (C).
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of the knee3e5,21. Conversely, there also exists a tonic in-
hibitory system in joints in which neuropeptides such as
galanin, somatostatin and endomorphin-1 reduce the
mechanosensitivity of primary afferent neurones3,12,22.
The present study examined another prominent neuropep-
tide, VIP, and found that local administration of the peptide
leads to the peripheral sensitization of rat knee joint primary
afferents. This is reﬂected in an enhanced ﬁring rate during
normal and noxious movement of the knee joint following
close intra-arterial injection of VIP. Pre-administration of
the selective VIP receptor antagonist VIP6e28 blocked the
sensitizing effect of VIP conﬁrming that VIP was acting on
VPAC receptors located in the knee. These ﬁndings are
consistent with behavioural studies measuring hindlimb
incapacitance and plantar algesiometry which showed that
intra-articular injection of VIP caused an increase in knee
joint allodynia and secondary hyperalgesia in rats19. Thus,
activation of articular VPAC receptors leads to enhanced
joint mechanosensitivity and consequently a heightened
pain state. Similar ﬁndings have been reported in dorsal
horn neurones which become hypersensitive to mechano-
sensory input following intrathecal application of VIP23,24.
In addition, VIP receptor agonists have been found to
have an excitatory effect on previously silent dorsal horn
neurones25 while blockade of central VPAC receptors by
VIP6e28 inhibited neuronal ﬁring rate in response to noxious
Fig. 4. Induction of OA signiﬁcantly increased ﬁring rate of afferent
nerve ﬁbres during non-noxious (A) and noxious (B) rotation of
the knee joint. ***P< 0.001 unpaired Student’s t test. Data are
shown as mean S.E.M. n¼ 12 ﬁbres for the control group and
n¼ 18 ﬁbres for the OA group.mechanical stimulation of the skin24. While these ﬁndings
outline a clear role for VIP in the central neurotransmission
of pain, the present study implicates VIP involvement in
peripheral nociceptive processes as well.
The mechanism by which VIP exerts its pro-nociceptive
effects may be related to the accumulation of cyclic adeno-
sine monophosphate (cAMP). Activation of VPAC receptors
causes the stimulation of adenylyl cyclase leading to cAMP
production and enhanced protein kinase A activity. Periph-
eral injection of forskolin, which promotes cAMP generation,
results in mechanical hyperalgesia26 while inhibitors of
cAMP and protein kinase A activity have been shown to
reduce mechanical hyperalgesia27. Thus, the heightened
mechanosensitivity of knee joint afferent nerve ﬁbres
described here may be due to VIP-mediated activation of
the cAMP-protein kinase A metabolic pathway.
The present study also found that the VPAC receptor an-
tagonist VIP6e28 had no signiﬁcant effect on mechanosensi-
tivity in the normal knee joint. This observation is consistent
with other studies which found that intrathecal application of
Fig. 5. Effect of close intra-arterial injection of the VPAC receptor
antagonist VIP6e28 on knee joint afferent activity in normal (open
circles) and in OA (black squares) knee joints in response to non-
noxious (A) and noxious (B) rotation of the knee joint. VIP6e28
had no signiﬁcant effect on afferent ﬁring rate in the normal knee
joint but reduced activity signiﬁcantly in the OA joint. Desensitizing
effect of VIP6e28 was maximal after 3 min; *P< 0.05; **P< 0.01;
***P< 0.001; Bonferroni post-test. Dotted line represents base
line. Data are shown as mean S.E.M.; n¼ 12 ﬁbres for the control
group and n¼ 18 ﬁbres for the OA group.
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stimulation after sciatic nerve transection, but not in an in-
tact nerve group10. Similarly, selective antagonism of VIP
receptors inhibited mustard oil-induced activity of dorsal
horn neurons in rats with experimental neuropathy25. These
studies support the hypothesis that VIP plays a minor role
in the modulation of nerve sensitivity under normal physio-
logical conditions, but seems to contribute to pain neuro-
transmission in pathological states such as peripheral
neuropathy10,28e31 and as shown here in OA.
MECHANOSENSITIVITY IN OA JOINTS
One of the most prominent features but least studied fac-
ets of OA is the development and persistence of chronic
pain. In the present investigation, OA was modelled by in-
tra-articular injection of sodium MIA which leads to massive
cartilage degradation with concomitant OA-like lesions16.
MIA causes an initial inﬂammatory response which is re-
solved by day 1418. Behavioural experiments have vali-
dated MIA as a viable model to assess OA pain18,19,32.
This study presents the ﬁrst electrophysiological evidence
that OA induces a dramatic sensitization of knee joint
Fig. 6. Doseeresponse relationship showing the effect of VIP6e28
on normal knee joint (open circles) and on OA knee joint (black
squares) afferent ﬁbres during non-noxious (A) and noxious (B)
rotation of the knee joint. Compared to control, the desensitizing ef-
fect of VIP6e28 in OA knee joints was statistically signiﬁcant (two-
way ANOVA P< 0.001; n¼ 12 ﬁbres for the control group and
n¼ 18 ﬁbres for the OA group; *P< 0.05; **P< 0.01; Bonferroni
post-test. Data are means S.E.M.afferents during normal and noxious hyper-rotation of the
knee joint. Other studies have shown that joint inﬂammation
causes a long lasting sensitization of type III and type IV af-
ferents to mechanical stimuli, leading to the sensation of
joint pain2,12,33e35. Low threshold afferents were shown to
have increased responsiveness in the working range of
the joint and high threshold afferents exhibited reduced
thresholds such that normal joint movements could now ac-
tivate nociceptive units. In addition, many type III and type
IV ﬁbres generate ongoing discharges in inﬂamed joints
even when the joint remains in a resting position. This tonic
afferent input is thought to be the neural basis of inﬂamma-
tory joint pain2,34. The present study provides the ﬁrst
evidence that similar sensitizing processes, such as in-
creased ﬁring rate and potential silent nociceptor activation
also occur during the development of OA. This observation
implies that the neurophysiological basis of OA pain
may also involve the sensitization of joint afferent ﬁbres.
Future studies are therefore indicated to characterise the
Fig. 7. Typical recording from an OA knee joint primary afferent in
response to non-noxious and noxious rotation (torque) of the joint
(A). Close intra-arterial injection of 109 mol of the VPAC receptor
antagonist VIP6e28 caused a signiﬁcant reduction in afferent ﬁring
rate for the same level of torque (B). Response of a single unit to
close intra-arterial application of KCL at the end of the experiment
conﬁrming that administered drug solutions reached the mechano-
sensory nerve endings (C).
1161Osteoarthritis and Cartilage Vol. 14, No. 11mediators involved in the sensitization of peripheral nerves
during OA progression.
VIP6e28 IN THE MIA MODEL OF OA
VIP was discovered in the synovial ﬂuid of arthritis pa-
tients nearly 20 years ago suggesting that this polypeptide
may be involved in the pathophysiology of arthritis36; how-
ever, the exact role of VIP in arthritis and joint pain is still
unclear. In the present study we show for the ﬁrst time
that close intra-arterial administration of the VPAC receptor
antagonist VIP6e28 signiﬁcantly decreased afferent ﬁring
rate during normal movement and noxious hyper-rotation
of an OA knee. Having already established that VIP in-
creases joint mechanosensitivity, the ability of VIP6e28 to in-
hibit afferent ﬁring rate in the MIA model suggests that VIP
is released into OA knee joints causing peripheral sensitiza-
tion of mechanosensory neurones leading to nociception.
This ﬁnding is consistent with behavioural experiments
which showed a reduction of pain perception after intra-
articular injection of VIP6e28 into OA knee joints
19 The mech-
anism of action of VIP in the OA joint is likely via the cAMP/
protein kinase A pathway described above. Interestingly in
other studies, incubation of VIP with blood cells procured
from OA patients resulted in a discrete increase in produc-
tion of interleukin-1b (IL-1b) IL-1b, interleukin-6 (IL-6), and
tumour necrosis factor-alpha (TNFa)37. Thus, it is possible
that stimulation of synovial VPAC receptors by VIP in OA
knees could cause the secondary release of pro-inﬂamma-
tory cytokines which in turn sensitize joint afferent nerve ter-
minals leading to heightened mechanosensitivity and pain.
The relationship between VIP and inﬂammatory cytokine
activity in OA pain warrants further investigations.
Other studies examining the role of VIP in joint physiology
found that topical application of the neuropeptide onto the
capsular surface of normal rat knee joints caused a dose-
dependent increase in synovial blood ﬂow11. This revelation
in conjunction with the results described here implies a
pro-inﬂammatory role for VIP in joint pathophysiology. In
contrast, it has been speculated that VIP may act as an anti-
inﬂammatory agent since the severity of collagen-induced
arthritis in mice was signiﬁcantly reduced by VIP treat-
ment38e40, although nociception was not investigated in
these studies. The reason for these conﬂicting views may
be related to differences in animal model used or mode of
VIP administration. Further clariﬁcation is needed to deter-
mine the precise role of VIP in joint function and disease.
In summary, the present study shows for the ﬁrst time that
VIP sensitizes normal knee joint primary afferents and that
blockade of peripheral VPAC receptors by local injection of
the VIP antagonist VIP6e28 inhibits the sensitizing effect of
VIP. In a model of OA, we revealed that afferent knee joint
ﬁbres are highly sensitized after induction of OA, which is
reﬂected by an enhanced ﬁring rate during joint movement
and reduced mechanical threshold. The ﬁnding that VIP6e28
had no effect in the normal knee joint but signiﬁcantly re-
duced mechanonociception in an OA knee joint suggests
that during OA, endogenous release of VIP sensitizes affer-
ent nerve ﬁbres leading to the generation of joint pain. Thus,
by reducing the nociceptive input to the central nervous sys-
tem, VIP6e28 has the potential to ameliorate the debilitating
symptoms of OA pain.
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